IndraLab
Statements
reach
"Whilst it may be questioned whether the treatment with BLD-2736 may have instead decreased full-length ataxin-3 through effects on the expression of EGFP-ataxin-3 via an effect on transcription, we previously demonstrated that treatment with calpeptin decreased the presence of full length human ataxin-3 protein, without altering the levels of human ataxin-3 mRNA, and that this effect was prevented by cotreatment with the autophagy inhibitor, chloroquine [43]."
| PMC